Drug profile · INN
insulin glargine-aglr
REZVOGLAR
insulin glargine-aglr (REZVOGLAR) is a insulin receptor agonist. Route of administration: injection. Current US regulatory status: approved.
Drug details — insulin glargine-aglr
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
insulin glargine-aglr (REZVOGLAR) is a insulin receptor agonist. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Insulin receptor agonist
Primary target: Insulin receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is insulin glargine-aglr?
insulin glargine-aglr (REZVOGLAR) is a insulin receptor agonist. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for insulin glargine-aglr?
REZVOGLAR is a marketed brand name for insulin glargine-aglr. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of insulin glargine-aglr?
insulin glargine-aglr has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.